SCHEMBL6423540

SCHEMBL6423540

COc1ccc(C(=O)N2c3ccccc3C(N3CCCc4cc(NC(C)=O)ccc43)CC2C)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.49
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
ALDH1A1 P00352 2/20 0.46
TSHR P16473 2/20 0.45
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NR3C1 P04150 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTGDR2 Q9Y5Y4 2/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BRD4 O60885 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6420245 0.94 MCL1 (0.49) MCL1PDE4APDE4BPDE4CPDE4D
SCHEMBL6420227 0.90 MCL1 (0.45) MCL1PDE4APDE4BPDE4CPDE4D
SCHEMBL6419674 0.89 PDE4A (0.59) MCL1PDE4APDE4BPDE4CPDE4D
SCHEMBL6421828 0.88 MCL1 (0.52) MCL1PDE4APDE4BPDE4CPDE4D
SCHEMBL6419337 0.87 MCL1 (0.52) MCL1PDE4APDE4BPDE4CPDE4D
SCHEMBL6419351 0.86 MCL1 (0.58) MCL1PDE4APDE4BPDE4CPDE4D
SCHEMBL6418749 0.83 MCL1 (0.51) MCL1PDE4APDE4BPDE4CPDE4D
SCHEMBL6419430 0.83 MCL1 (0.61) MCL1PDE4APDE4BPDE4CPDE4D
SCHEMBL6420280 0.82 PDE4A (0.52) MCL1PDE4APDE4BPDE4CPDE4D
SCHEMBL6420553 0.81 MCL1 (0.45) MCL1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930104-B2 Heterocyclic derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040157850-A1 Novel heterocyclic derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
EP-1382598-A1 NOVEL HETEROCYCLIC DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2004-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157850-A1 Novel heterocyclic derivatives APP, BACE1, PSEN1 MCL1 3567/4885PDE4A 1805/4885PDE4B 2480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.